Prognostic Features of Surgical Stage I Uterine Carcinosarcoma
- 1 November 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 31 (11), 1653-1661
- https://doi.org/10.1097/pas.0b013e3181161ba3
Abstract
Uterine carcinosarcomas (CSs) are aggressive neoplasms, with 5-year overall survival (OS) rates of less than 35%. They are customarily separated into types harboring either heterologous or homologous mesenchymal elements, but the prognostic significance of this finding is controversial. Our goal was to study clinicopathologic features of possible prognostic relevance in surgical stage I uterine CS. A retrospective clinical and histopathologic review was performed for all women diagnosed with surgical stage I uterine CS. These tumors were compared with stage I high-grade endometrial (HGEm) carcinomas for clinical outcomes. There were 42 cases of surgical stage I uterine CS identified between January 1990 and January 2004. The disease-free survival and OS rates for patients with stage I CS were significantly worse compared with stage I HGEm (P=0.001; P=0.01). The median disease-free survival for patients with heterologous CS was 15 months and had not been reached for women with homologous CS (P=0.001). The 3-year OS rates were 45% versus 93% in women with heterologous compared with homologous stage I CS (P90%. Homologous stage I CSs have survival outcomes that are similar to HGEm. This further supports the concept that homologous stage I CSs are carcinomas with sarcomatoid features, not sarcomas. More importantly, the presence of heterologous sarcomatous elements is a powerful negative prognostic factor in surgical stage I uterine CS.Keywords
This publication has 28 references indexed in Scilit:
- Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancerGynecologic Oncology, 2005
- Is there a difference in outcome between stage I–II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?International Journal of Radiation Oncology*Biology*Physics, 2002
- Paclitaxel in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group StudyGynecologic Oncology, 2001
- Prognostic factors in uterine carcinosarcomaCancer, 1998
- Malignant Mixed Mullerian Tumor Versus High-Grade Endometrial Carcinoma and Aggressive Variants of Endometrial CarcinomaInternational Journal of Gynecological Pathology, 1995
- Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *JNCI Journal of the National Cancer Institute, 1994
- Treatment of uterine sarcomasCancer, 1990
- Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 100 cases with a review of the literatureHuman Pathology, 1990
- The Significance of Epithelial Differences in Mixed Mesodermal Tumors of the UterusThe American Journal of Surgical Pathology, 1990
- Malignant mixed müllerian tumors of the uterusThe American Journal of Surgical Pathology, 1979